AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22417767 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 19948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg) with diphenhydramine (CYP2D6 inhibitor)
Number of subjects: 36
Study 19948945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 36
Study 19948945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (CYP2D6 inhibitor)
Number of subjects: 36
Study 18544981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 18544981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy
Number of subjects: 0
Study 18544981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0
Study 18544981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with hormones
Number of subjects: 0
Study 16340187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg by rectiole, followed by 10 mg tablets twice daily for 3 days
Number of subjects: 880
Study 16340187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 14596675 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (AA)
Number of subjects: 28
Study 14596675 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric control
Number of subjects: 28
Study 14596675 — intervention group
Group type: COMPARATOR
Intervention: Fasting control
Number of subjects: 28
Study 11757637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (CT) scan
Number of subjects: 0
Study 11757637 — intervention group
Group type: COMPARATOR
Intervention: Lung cancer screening
Number of subjects: 0
Study 9326185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients informed about the real nature of the cap of the pill bottle
Number of subjects: 68
Study 9326185 — intervention group
Group type: COMPARATOR
Intervention: Patients not informed about the real nature of the cap of the pill bottle
Number of subjects: 68
Study 8330924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia (16 mg/kg/day orally)
Number of subjects: 30
Study 8330924 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (vitamin K, antibiotics, biliary drainage)
Number of subjects: 30
Study 3524221 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 106
Study 3524221 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 106
Study 2504673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 20 mg twice a day
Number of subjects: 18
Study 2504673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained released isosorbide 40 mg once daily
Number of subjects: 18
Study 2504673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice a day
Number of subjects: 18
Study 2504673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31525422 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrospun nanoscale P(LLA-CL)/fibrinogen patch
Number of subjects: 172
Study 31525422 — intervention group
Group type: COMPARATOR
Intervention: Porcine small intestine submucosa patch
Number of subjects: 172
Study 31525422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study 27138609 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive intramedullary fixation with Sonoma Crx device
Number of subjects: 75
Study 27138609 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mm locking compression plate (LCP)
Number of subjects: 75
Study 26003584 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention aimed at promoting employees' schedule control and supervisor support for personal and family life.
Number of subjects: 93
Study 26003584 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention).
Number of subjects: 93
Study 23554858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold temperature (1°C decrease in air temperature)
Number of subjects: 16254
Study 23554858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold temperature (5°C decrease in mean temperature)
Number of subjects: 16254
Study 23554858 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher barometric pressure, more hours of sunshine, and lower humidity
Number of subjects: 16254
Study 22014673 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles for People with Disabilities health promotion program
Number of subjects: 95
Study 19211938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (400 mg twice daily)
Number of subjects: 78
Study 17092520 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid (AA) daily infusion for 7 days
Number of subjects: 86
Study 17092520 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily infusion for 7 days
Number of subjects: 86
Study 17092520 — intervention group
Group type: EXPERIMENTAL
Intervention: Arundic acid (AA)
Number of subjects: 86
Study 17092520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17092520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AA and placebo
Number of subjects: 86
Study 12848402 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Visiting support
Number of subjects: 0
Study 12848402 — intervention group
Group type: COMPARATOR
Intervention: Self-exclusion from Health Visiting support
Number of subjects: 0
Study 14564617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 31
Study 14564617 — intervention group
Group type: COMPARATOR
Intervention: Nil per os (NPO)
Number of subjects: 31
Study 8906519 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg cilazapril
Number of subjects: 40
Study 8906519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1844105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (2 g with anesthetic induction)
Number of subjects: 207
Study 1844105 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (continued administration for 48 hours)
Number of subjects: 207
Study 1844105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 207
Study 1844105 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 207
Study 6127946 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 6127946 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study 6127946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31628428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily continuously
Number of subjects: 269
Study 31628428 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil 0.5-0.8 mg/kg for ≤12 cycles
Number of subjects: 269
Study 31495668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task walking (DTW)
Number of subjects: 22
Study 31495668 — intervention group
Group type: COMPARATOR
Intervention: Single-task treadmill walking (TMW)
Number of subjects: 22
Study 27677100 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mL of methylprednisolone (40 mg/mL) and 1.5 mL of 2% lidocaine with 0.5 mL of saline (Group S)
Number of subjects: 40
Study 27677100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of leukocyte‐free PRP with 0.5 mL of calcium chloride (Group P)
Number of subjects: 40
Study 26400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (30 g of whey protein daily)
Number of subjects: 196
Study 26400966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.1 g protein daily)
Number of subjects: 196
Study 26400966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Whey protein and Placebo)
Number of subjects: 196
Study 23332435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surfaced microthreaded implants
Number of subjects: 34
Study 23332435 — intervention group
Group type: COMPARATOR
Intervention: Machined-neck implants
Number of subjects: 34
Study 21690317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (open-label trial)
Number of subjects: 0
Study 21690317 — intervention group
Group type: COMPARATOR
Intervention: Nicotine transdermal patch (placebo-controlled trial)
Number of subjects: 0
Study 21690317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both trials
Number of subjects: 0
Study 19068562 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 19068562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 16847405 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) plus stavudine (d4T)
Number of subjects: 509
Study 12742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 254
Study 12742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 45 mg
Number of subjects: 254
Study 12742979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 254
Study 12742979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 11078176 — intervention group
Group type: EXPERIMENTAL
Intervention: Random spot urinary albumin creatinine ratio (ACR) >30 mg/g
Number of subjects: 109
Study 11078176 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ACR
Number of subjects: 109
Study 11078176 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR in men with LVH
Number of subjects: 109
Study 8764904 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 8764904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1458788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 oral pulses of 100 mg prednisolone
Number of subjects: 30
Study 1458788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 intravenous pulses of 1000 mg methylprednisolone (MP)
Number of subjects: 30
Study 1458788 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 30
Study 6148470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 10 mg/kg 8-hourly for 10 days
Number of subjects: 127
Study 6148470 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine 15 mg/kg daily for 10 days
Number of subjects: 127
Study 31427204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 31427204 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 29875287 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (Group A)
Number of subjects: 52
Study 29875287 — intervention group
Group type: COMPARATOR
Intervention: Conservative follow-up (Group B)
Number of subjects: 52
Study 29875287 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 52
Study 28245790 — intervention group
Group type: EXPERIMENTAL
Intervention: History of coronary heart disease (CHD)
Number of subjects: 254
Study 28245790 — intervention group
Group type: COMPARATOR
Intervention: No history of coronary heart disease (non-CHD)
Number of subjects: 254
Study 26141495 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial surgical glove
Number of subjects: 16
Study 26141495 — intervention group
Group type: COMPARATOR
Intervention: Non-antimicrobial surgical glove
Number of subjects: 16
Study 23381484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Number of subjects: 40
Study 21085467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (plant-based repellent) twice daily for one week every second week
Number of subjects: 0
Study 21085467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin every fourth week for one week
Number of subjects: 0
Study 21085467 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no application of repellent)
Number of subjects: 0
Study 21085467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (cohort A)
Number of subjects: 0
Study 21085467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (cohort B)
Number of subjects: 0
Study 21085467 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (cohort C)
Number of subjects: 0
Study 18434457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine 1%
Number of subjects: 48
Study 18434457 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine/diazepam
Number of subjects: 48
Study 17472039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush (SC)
Number of subjects: 61
Study 17472039 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 61
Study 12897359 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care programme
Number of subjects: 248
Study 10953658 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0
Study 9323816 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits (bolus heparin dose reduced by 25% to 225 IU/kg, ACT limit 300 sec)
Number of subjects: 14
Study 9323816 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 14
Study 9323816 — intervention group
Group type: COMPARATOR
Intervention: Control group (noncoated CPB sets, normal heparinization with bolus 300 IU/kg)
Number of subjects: 14
Study 7903137 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of whole blood tested negative for HIV antibodies
Number of subjects: 116
Study 7903137 — intervention group
Group type: COMPARATOR
Intervention: Treatment for malaria and hookworm alone (no transfusion)
Number of subjects: 116
Study 3839991 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg intrathecal morphine preoperatively
Number of subjects: 0
Study 3839991 — intervention group
Group type: COMPARATOR
Intervention: Intravenous papaveretum peroperatively
Number of subjects: 0
Study 30902428 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for weight loss
Number of subjects: 0
Study 30902428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29959765 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 71
Study 29959765 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 71
Study 29959765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 71
Study 27072050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 111
Study 27072050 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 111
Study 24217336 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Number of subjects: 122
Study 24217336 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 122
Study 22074464 — intervention group
Group type: EXPERIMENTAL
Intervention: Visian Implantable Collamer Lens (ICL) implantation
Number of subjects: 63
Study 22074464 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided laser epithelial keratomileusis (WFG-LASEK)
Number of subjects: 63
Study 20520284 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 123
Study 18801964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-adapt
Number of subjects: 8
Study 18801964 — intervention group
Group type: COMPARATOR
Intervention: HCHO
Number of subjects: 8
Study 16160211 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifier scale
Number of subjects: 790
Study 16160211 — intervention group
Group type: COMPARATOR
Intervention: Standard rating scale (SRS)
Number of subjects: 790
Study 12867218 — intervention group
Group type: EXPERIMENTAL
Intervention: IM olanzapine 10 mg
Number of subjects: 311
Study 12867218 — intervention group
Group type: COMPARATOR
Intervention: IM haloperidol 7.5 mg
Number of subjects: 311
Study 12867218 — intervention group
Group type: COMPARATOR
Intervention: PO haloperidol (5-20 mg/d)
Number of subjects: 311
Study 12867218 — intervention group
Group type: EXPERIMENTAL
Intervention: PO olanzapine (5-20 mg/d)
Number of subjects: 311
Study 10394281 — intervention group
Group type: COMPARATOR
Intervention: Exercises and manipulation in patients with acute low back pain (0-4 weeks)
Number of subjects: 18
Study 10394281 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise program and workplace visits in patients with subacute low back pain (4-12 weeks)
Number of subjects: 18
Study 10394281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises in patients with chronic low back pain (>12 weeks)
Number of subjects: 18
Study 10394281 — intervention group
Group type: COMPARATOR
Intervention: Manipulation in patients with chronic low back pain (>12 weeks)
Number of subjects: 18
Study 10394281 — intervention group
Group type: COMPARATOR
Intervention: Different exercise regimens in patients with chronic low back pain (>12 weeks)
Number of subjects: 18
Study 8027280 — intervention group
Group type: EXPERIMENTAL
Intervention: High FSH group
Number of subjects: 48
Study 8027280 — intervention group
Group type: COMPARATOR
Intervention: Normal FSH group
Number of subjects: 48
Study 2644534 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (two-week hospitalization with continuous insulin infusion by external artificial pancreas)
Number of subjects: 26
Study 2644534 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (NPH insulin, 1 U per kg body weight per day, in two divided doses)
Number of subjects: 26
Study 789852 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2 mg twice daily for 30 days)
Number of subjects: 30
Study 789852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30926576 — intervention group
Group type: EXPERIMENTAL
Intervention: PMERT (postmastectomy highly conformal electron radiation therapy with bolus)
Number of subjects: 807
Study 30926576 — intervention group
Group type: COMPARATOR
Intervention: PMPhRT (postmastectomy highly conformal photon radiation therapy without bolus)
Number of subjects: 807
Study 30926576 — intervention group
Group type: EXPERIMENTAL
Intervention: PMERT
Number of subjects: 807
Study 30926576 — intervention group
Group type: COMPARATOR
Intervention: PMPhRT
Number of subjects: 807
Study 28806338 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation of CI1 during a 4-week adaptation period after CI2 activation
Number of subjects: 16
Study 28806338 — intervention group
Group type: COMPARATOR
Intervention: Continued use of CI1 during a 4-week adaptation period after CI2 activation
Number of subjects: 16
Study 25711330 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD prevalence in HIV-positive adults
Number of subjects: 1026
Study 25711330 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and pack-years of smoking
Number of subjects: 1026
Study 25711330 — intervention group
Group type: EXPERIMENTAL
Intervention: Region effect on FEV1:FVC ratio
Number of subjects: 1026
Study 23826890 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal preparation of myrrh, chamomile extract, and coffee charcoal
Number of subjects: 96
Study 23826890 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 96
Study 20499304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapylin combined with chemotherapy
Number of subjects: 132
Study 20499304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 18611338 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation (OTI) with GlideScope video laryngoscope
Number of subjects: 60
Study 18611338 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal intubation (NTI) with GlideScope video laryngoscope
Number of subjects: 60
Study 16669964 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg o.d. plus aspirin 325 mg o.d.
Number of subjects: 100
Study 16669964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg b.d. plus aspirin 325 mg o.d.
Number of subjects: 100
Study 16669964 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin 325 mg o.d.
Number of subjects: 100
Study 12756159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preoperative and intraoperative methylprednisolone (30 mg/kg 4 hours before bypass and in bypass prime)
Number of subjects: 29
Study 12756159 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative methylprednisolone only (30 mg/kg)
Number of subjects: 29
Study 11205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional phantoms used in the first round of audit visits
Number of subjects: 0
Study 11205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-filled three-dimensional phantom
Number of subjects: 0
Study 11205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom for assessing dose in the junction region
Number of subjects: 0
Study 9183308 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Fenfluramine 15 mg twice daily for 12 weeks
Number of subjects: 48
Study 9183308 — intervention group
Group type: EXPERIMENTAL
Intervention: High compliance with the drug regimen
Number of subjects: 48
Study 9183308 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history of obesity
Number of subjects: 48
Study 1554631 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with water alone
Number of subjects: 99
Study 1554631 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing with soap and water
Number of subjects: 99
Study 1554631 — intervention group
Group type: COMPARATOR
Intervention: Not washing
Number of subjects: 99
Study 3890523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole therapy
Number of subjects: 32
Study 3890523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31088515 — intervention group
Group type: EXPERIMENTAL
Intervention: In2Care® mosquito traps
Number of subjects: 0
Study 31088515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29431598 — intervention group
Group type: EXPERIMENTAL
Intervention: M. charantia (2000 mg/day)
Number of subjects: 24
Study 29431598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24